PubMed Health⌕ Search

PubMed · 1792072

Surgery for advanced thyroid malignancy.

Abstract

Advanced thyroid malignancy can occur early in the course of the disease, or as late as 20 to 25 years after the initial diagnosis. The basic treatment is total thyroidectomy with central node dissection regardless of the histologic type. the nonresectable disease is treated with 131I if the tumor has iodine uptake. Further ablative surgery for resectable disease is governed by location and histologic cell type. Otherwise external radiation and chemotherapy (Adriamycin) is used. Anaplastic, primary squamous cell, and pure papillary and some predominantly papillary carcinomas and some Hürthle cell carcinomas do not have 131I uptake and fall into this latter category. The surgeon must be aware of this problem in the noniodine uptake tumors and take special care to remove all surgically resectable disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Loré. 1991. Surgery for advanced thyroid malignancy.. https://pubmed.health/record/pubmed%3A1792072/surgery-for-advanced-thyroid-malignancy

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

[Fibromyalgia. Diagnostics--disease approach--therapy].

Fibromyalgia is a complex of symptoms predominantly affecting females and consisting of widespread pain. Etiology and pathogenesis are not sufficiently known yet, however, there is the assumption that fibromyalgia is looked at as being an illness with biological, psychological, and social aspects. Therefore, the treatment of fibromyalgia calls for a multimodal therapy approach. The importance of fibromyalgia has been recognized within the German health system by creating the new ICD code M79.70 and by assigning fibromyalgia its own rheumatologic DRG (I79Z). In future research of fibromyalgia special attention needs to be placed upon gender-specific problems.

Combined Modality Therapy↗

Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes.

Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limited. We analyzed the Surveillance Epidemiology End Results (SEER) registry for population-based data on efficacy of post-operative RT for +LN patients after RP. As LN data have only been captured by SEER since 1988, we analyzed data for 1988-1992, with specific attention to 10-year relative survival (defined as observed survival divided by the survival of a gender-, age- and race-matched population cohort without disease). Specifically analyzed were data for 1921 patients with nonmetastatic prostate cancer who underwent surgery alone, or surgery followed by RT, and who had +LNs documented. SEER does not code the interval between surgery and RT, so the ratio of patients receiving salvage versus adjuvant therapy is unknown. Using follow-up data through 2002, post-diagnosis survival was examined by number of +LNs. There was no significant relative survival benefit for +LN patients receiving post-operative RT (chi(2)P=0.270). These data do not support routine use of post-operative RT for patients with +LNs in the surgical specimen.

Combined Modality Therapy↗